How much capital did Oryzon Genomics, S.A. raise in its completed capital increase?

Oryzon Genomics, S.A. completed a €12 million gross capital increase through the issuance of 4,444,445 new ordinary shares. The offering was structured without the issuance of warrants.

What was the subscription price in Oryzon Genomics, S.A.'s capital increase?

The subscription price was €2.70 per share. Oryzon Genomics, S.A. said this represented a 14.15% discount to the five-day volume-weighted average price of €3.1449 and a 12.68% discount to the June 30 closing price of €3.092 per share.

How will Oryzon Genomics, S.A. use the proceeds from its completed capital increase?

Oryzon Genomics, S.A. said the proceeds will strengthen its balance sheet to support corporate development initiatives, advance the clinical development of iadademstat for acute myeloid leukaemia, progress other clinical programmes in haematology and psychiatry, and cover general and administrative expenses and financial obligations.

What clinical programme is Oryzon Genomics, S.A. prioritising with the new funding?

Oryzon Genomics, S.A. said the funding will support the clinical development of iadademstat for acute myeloid leukaemia. It also said the proceeds will progress its other ongoing clinical programmes in haematology and psychiatry.

What did Oryzon Genomics, S.A. agree with COFIDES's Social Impact Fund?

Oryzon Genomics, S.A. entered into a share subscription agreement under which the Social Impact Fund, managed by COFIDES, has committed as an anchor investor to subscribe in the future for newly created Oryzon shares for a total investment amount of €25 million, including nominal value plus issue premium. The commitment is subject to certain corporate, financial, business and impact-related conditions.

When can COFIDES's Social Impact Fund subscribe for new Oryzon Genomics, S.A. shares?

The commitment applies to any future capital increase that Oryzon Genomics, S.A. may undertake within six months of the execution of the share subscription agreement. The period may be extended by mutual agreement between the parties.

What restrictions apply to the proceeds from the COFIDES agreement with Oryzon Genomics, S.A.?

Oryzon Genomics, S.A. has undertaken to use the proceeds for research and development activities directly or indirectly related to products in the central nervous system, oncology and haematology. At least 40% of the proceeds must be allocated to medicines addressing unmet medical needs in mental health, particularly the company's programme in borderline personality disorder and other psychiatric conditions.

How does Oryzon Genomics, S.A. describe its business?

Oryzon Genomics, S.A. describes itself as a clinical-stage biopharmaceutical company and a global leader in epigenetics. The announcement refers to programmes in oncology, haematology, the central nervous system and psychiatry.

What did Oryzon Genomics, S.A.'s CEO say about the completed funding?

Chief Executive Officer Dr Carlos Buesa said the funding strengthens Oryzon Genomics, S.A.'s ability to execute its clinical strategy and provides financial flexibility to accelerate priority programmes while exploring strategic opportunities. He also said the acute myeloid leukaemia programme was attracting increasing attention among international oncology experts, pharmaceutical companies and specialised investors.

What did Oryzon Genomics, S.A.'s CEO say about the COFIDES partnership?

Dr Carlos Buesa said the partnership with COFIDES's Social Impact Fund represents a financial commitment and recognition of the potential of Oryzon Genomics, S.A.'s mental health programmes. He said the agreement strengthens the company's ability to accelerate psychiatric therapy development and facilitates engagement with specialised international investment funds.

Where are Oryzon Genomics, S.A.'s shares identified in the announcement?

The announcement identifies Oryzon Genomics, S.A. by ISIN Code ES0167733015 and the symbol ORY. It does not state a trading venue in the provided content.

Who acted as placement agents for Oryzon Genomics, S.A.'s capital increase?

Singular Bank acted as placement agent in Spain, while All-Invest acted as placement agent in the EU and the UK. Banco Sabadell, S.A. acted as Agent Bank and Technical Pre-Financing Entity, and Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal counsel to Oryzon Genomics, S.A.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement

Published Wednesday, 01 July 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Financing
Published: Wednesday, 01 July 2026
Source announcement: oryzon.com

Key figures
Measure	Figure	Compared with
Gross capital increase	€12 million	Not stated
Subscription price	€2.70 per share	Not stated
Discount to the five-day volume-weighted average price (VWAP)	14.15%	€3.1449 in the five-day volume-weighted average price (VWAP) (14.15%)
Investment amount (nominal plus issue premium)	€25 million	Not stated

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics, S.A. (ORY) announced a completed capital increase and a share subscription agreement with the Social Impact Fund managed by COFIDES.

The capital increase raised €12 million gross through 4,444,445 new ordinary shares priced at €2.70 each.
The offering did not include warrants; Singular Bank and All-Invest acted as placement agents.
The €2.70 price represented discounts of 14.15% to the five-day VWAP of €3.1449 and 12.68% to June 30's closing price of €3.092.
Proceeds will strengthen the balance sheet, advance iadademstat, progress other hematology and psychiatry programs, and cover expenses and financial obligations.
The Social Impact Fund, managed by Compañía Española de Financiación del Desarrollo (COFIDES), S.A., S.M.E., committed to subscribe for €25 million of newly created Oryzon shares, subject to corporate, financial, business and impact-related conditions.

The commitment applies to future capital increases within six months of execution, extendable by mutual agreement. Proceeds must fund research and development related to central nervous system, oncology and hematology products; at least 40% must address unmet mental-health needs, including borderline personality disorder and other psychiatric conditions.

Investor FAQs

Oryzon Genomics, S.A. announced the completion of a €12 million gross capital increase and the signing of a share subscription agreement with the Social Impact Fund managed by COFIDES. The future subscription commitment is subject to certain corporate, financial, business and impact-related conditions.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON raises €12 million and signs a financing agreement with COFIDES to strengthen its balance sheet and accelerate its clinical programs
Published: Wednesday, 01 July 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…